It was good news for Novartis and bad news for Merck KGaA this week as regulators handed down their decisions on each company’s multiple sclerosis (MS) drug candidate.
No Shortage of Hopefuls in the Multibillion-Dollar Blood Thinner Business
Patients hoping for a new alternative to the blockbuster blood thinner Plavix will have to wait a bit longer for a verdict on a promising candidate.
Onyx Pharmaceuticals to Acquire Proteolix
Onyx Pharmaceuticals has agreed to purchase private biotechnology company Proteolix for $276 million in cash.
